DNA Methylation as a Potential Molecular Mechanism in X-linked Dystonia-Parkinsonism.
DNA methylation
GATA2
TAF1
X-linked dystonia-parkinsonism
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
17
10
2019
revised:
02
07
2020
accepted:
11
07
2020
pubmed:
12
9
2020
medline:
28
4
2021
entrez:
11
9
2020
Statut:
ppublish
Résumé
X-linked dystonia-parkinsonism is a neurodegenerative movement disorder. The underlying molecular basis has still not been completely elucidated, but likely involves dysregulation of TAF1 expression. In X-linked dystonia-parkinsonism, 3 disease-specific single-nucleotide changes (DSCs) introduce (DSC12) or abolish (DSC2 and DSC3) CpG dinucleotides and consequently sites of putative DNA methylation. Because transcriptional regulation tightly correlates with specific epigenetic marks, we investigated the role of DNA methylation in the pathogenesis of X-linked dystonia-parkinsonism. DNA methylation at DSC12, DSC3, and DSC2 was quantified by bisulfite pyrosequencing in DNA from peripheral blood leukocytes, fibroblasts, induced pluripotent stem cell-derived cortical neurons and brain tissue from X-linked dystonia-parkinsonism patients and age- and sex-matched healthy Filipino controls in a prospective study. Compared with controls, X-linked dystonia-parkinsonism patients showed striking differences in DNA methylation at the 3 investigated CpG sites. Using methylation-sensitive luciferase reporter gene assays and immunoprecipitation, we demonstrated (1) that lack of DNA methylation because of DSC2 and DSC3 affects gene promoter activity and (2) that methylation at all 3 investigated CpG sites alters DNA-protein interaction. Interestingly, DSC3 decreased promoter activity per se compared with wild type, and promoter activity further decreased when methylation was present. Moreover, we identified specific binding of proteins to the investigated DSCs that are associated with splicing and RNA and DNA binding. We identified altered DNA methylation in X-linked dystonia-parkinsonism patients as a possible additional mechanism modulating TAF1 expression and putative novel targets for future therapies using DNA methylation-modifying agents. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
X-linked dystonia-parkinsonism is a neurodegenerative movement disorder. The underlying molecular basis has still not been completely elucidated, but likely involves dysregulation of TAF1 expression. In X-linked dystonia-parkinsonism, 3 disease-specific single-nucleotide changes (DSCs) introduce (DSC12) or abolish (DSC2 and DSC3) CpG dinucleotides and consequently sites of putative DNA methylation. Because transcriptional regulation tightly correlates with specific epigenetic marks, we investigated the role of DNA methylation in the pathogenesis of X-linked dystonia-parkinsonism.
METHODS
DNA methylation at DSC12, DSC3, and DSC2 was quantified by bisulfite pyrosequencing in DNA from peripheral blood leukocytes, fibroblasts, induced pluripotent stem cell-derived cortical neurons and brain tissue from X-linked dystonia-parkinsonism patients and age- and sex-matched healthy Filipino controls in a prospective study.
RESULTS
Compared with controls, X-linked dystonia-parkinsonism patients showed striking differences in DNA methylation at the 3 investigated CpG sites. Using methylation-sensitive luciferase reporter gene assays and immunoprecipitation, we demonstrated (1) that lack of DNA methylation because of DSC2 and DSC3 affects gene promoter activity and (2) that methylation at all 3 investigated CpG sites alters DNA-protein interaction. Interestingly, DSC3 decreased promoter activity per se compared with wild type, and promoter activity further decreased when methylation was present. Moreover, we identified specific binding of proteins to the investigated DSCs that are associated with splicing and RNA and DNA binding.
CONCLUSIONS
We identified altered DNA methylation in X-linked dystonia-parkinsonism patients as a possible additional mechanism modulating TAF1 expression and putative novel targets for future therapies using DNA methylation-modifying agents. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Substances chimiques
TATA-Binding Protein Associated Factors
0
Transcription Factor TFIID
0
Histone Acetyltransferases
EC 2.3.1.48
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2220-2229Informations de copyright
© 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Lee LV, Rivera C, Teleg RA, et al. The unique phenomenology of sex-linked dystonia parkinsonism (XDP, DYT3, “Lubag”). Int J Neurosci 2011;121:3-11. https://doi.org/10.3109/00207454.2010.526728
Domingo A, Westenberger A, Lee LV, et al. New insights into the genetics of X-linked dystonia-parkinsonism (XDP, DYT3). Eur J Hum Genet 2015;23:1334-1340. https://doi.org/10.1038/ejhg.2014.292
Nolte D, Niemann S, Müller U. Specific sequence changes in multiple transcript system DYT3 are associated with X-linked dystonia parkinsonism. Proc Natl Acad Sci U S A 2003;100:10347-10352. https://doi.org/10.1073/pnas.1831949100
Makino S, Kaji R, Ando S, et al. Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism. Am J Hum Genet 2007;80:393-406.
Herzfeld T, Nolte D, Grznarova M, Hofmann A, Schultze JL, Müller U. X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-specific sequence change DSC3 in TAF1/DYT3 affects genes in vesicular transport and dopamine metabolism. Hum Mol Genet 2013;22:941-951. https://doi.org/10.1093/hmg/dds499
Domingo A, Amar D, Grütz K, et al. Evidence of TAF1 dysfunction in peripheral models of X-linked dystonia-parkinsonism. Cell Mol Life Sci 2016;73:3205-3215. https://doi.org/10.1007/s00018-016-2159-4
Ito N, Hendriks WT, Dhakal J, et al. Decreased N-TAF1 expression in X-linked dystonia-parkinsonism patient-specific neural stem cells. Dis Model Mech 2016;9:451-462. https://doi.org/10.1242/dmm.022590
Aneichyk T, Hendriks WT, Yadav R, et al. Dissecting the causal mechanism of X-linked dystonia-parkinsonism by integrating genome and transcriptome assembly. Cell 2018;172:897-909.e21. https://doi.org/10.1016/j.cell.2018.02.011
Rakovic A, Domingo A, Grütz K, et al. Genome editing in induced pluripotent stem cells rescues TAF1 levels in X-linked dystonia-parkinsonism. Mov Disord 2018;33:1108-1118. https://doi.org/10.1002/mds.27441
Bragg DC, Mangkalaphiban K, Vaine CA, et al. Disease onset in X-linked dystonia-parkinsonism correlates with expansion of a hexameric repeat within an SVA retrotransposon in TAF1. Proc Natl Acad Sci USA 2017;51(114):E11020-E11028. https://doi.org/10.1073/pnas.1712526114
Westenberger A, Reyes CJ, Saranza G, et al. A hexanucleotide repeat modifies expressivity of X-linked dystonia parkinsonism. Ann Neurol 2019;85:812-822. https://doi.org/10.1002/ana.25488
Klug M, Rehli M. Functional analysis of promoter CpG methylation using a CpG-free luciferase reporter vector. Epigenetics 2006;1:127-130. https://doi.org/10.4161/epi.1.3.3327
UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res 2019;47:D506-D515. https://doi.org/10.1093/nar/gky1049
Thomas PD, Campbell MJ, Kejariwal A, et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 2003;13:2129-2141. https://doi.org/10.1101/gr.772403
Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009;462:315-322. https://doi.org/10.1038/nature08514
Westenberger A, Rosales RL, Heinitz S, et al. X-linked dystonia-parkinsonism manifesting in a female patient due to atypical turner syndrome. Mov Disord 2013;28:675-678. https://doi.org/10.1002/mds.25369
Domingo A, Lee LV, Brüggemann N, et al. Woman with X-linked recessive dystonia-parkinsonism: clue to the epidemiology of parkinsonism in Filipino women? JAMA Neurol 2014;71:1177-1180. https://doi.org/10.1001/jamaneurol.2014.56
Mellén M, Ayata P, Heintz N. 5-Hydroxymethylcytosine accumulation in postmitotic neurons results in functional demethylation of expressed genes. Proc Natl Acad Sci U S A 2017;114:E7812-E7821. https://doi.org/10.1073/pnas.1708044114
Bajaj MS, Tyson DR, Steer SA, Kuppuswamy MN. Role of GATA motifs in tissue factor pathway inhibitor gene expression in malignant cells. Thromb Res 2001;101:203-211. https://doi.org/10.1016/S0049-3848(00)00393-5
Li Y-W, Wang J-X, Yin X, et al. Decreased expression of GATA2 promoted proliferation, migration and invasion of HepG2 in vitro and correlated with poor prognosis of hepatocellular carcinoma. PLoS One 2014;9:e87505. https://doi.org/10.1371/journal.pone.0087505
Yaguchi T, Nakano T, Gotoh A, Nishizaki T. Adenosine promotes GATA-2-regulated p53 gene transcription to induce HepG2 cell apoptosis. Cell Physiol Biochem 2011;28:761-770. https://doi.org/10.1159/000335770
Imagawa S, Yamamoto M, Miura Y. Negative regulation of the erythropoietin gene expression by the GATA transcription factors. Blood 1997;89:1430-1439.
Batmunkh C, Krajewski J, Jelkmann W, Hellwig-Bürgel T. Erythropoietin production: Molecular mechanisms of the antagonistic actions of cyclic adenosine monophosphate and interleukin-1. FEBS Lett 2006;580:3153-3160. https://doi.org/10.1016/j.febslet.2006.04.069
Laurent L, Wong E, Li G, et al. Dynamic changes in the human methylome during differentiation. Genome Res 2010;20:320-331. https://doi.org/10.1101/gr.101907.109
Gelfman S, Cohen N, Yearim A, Ast G. DNA-methylation effect on cotranscriptional splicing is dependent on GC architecture of the exon-intron structure. Genome Res 2013;23:789-799. https://doi.org/10.1101/gr.143503.112
Shukla S, Kavak E, Gregory M, et al. CTCF-promoted RNA polymerase II pausing links DNA methylation to splicing. Nature 2011;479:74-79. https://doi.org/10.1038/nature10442
Maunakea AK, Chepelev I, Cui K, Zhao K. Intragenic DNA methylation modulates alternative splicing by recruiting MeCP2 to promote exon recognition. Cell Res 2013;23:1256-1269. https://doi.org/10.1038/cr.2013.110
Yearim A, Gelfman S, Shayevitch R, et al. HP1 is involved in regulating the global impact of DNA methylation on alternative splicing. Cell Rep 2015;10:1122-1134. https://doi.org/10.1016/j.celrep.2015.01.038
Huang L, Fu H, Lin CM, Conner AL, Zhang Y, Aladjem MI. Prevention of transcriptional silencing by a replicator-binding complex consisting of SWI/SNF, MeCP1, and hnRNP C1/C2. Mol Cell Biol 2011;31:3472-3484. https://doi.org/10.1128/MCB.05587-11
Deneen B, Ho R, Lukaszewicz A, Hochstim CJ, Gronostajski RM, Anderson DJ. The transcription factor NFIA controls the onset of gliogenesis in the developing spinal cord. Neuron 2006;52:953-968. https://doi.org/10.1016/j.neuron.2006.11.019
Domcke S, Bardet AF, Adrian Ginno P, Hartl D, Burger L, Schübeler D. Competition between DNA methylation and transcription factors determines binding of NRF1. Nature 2015;528:575-579. https://doi.org/10.1038/nature16462
Reinius LE, Acevedo N, Joerink M, et al. Differential DNA methylation in purified human blood cells: implications for cell lineage and studies on disease susceptibility. PLoS One 2012;7:e41361. https://doi.org/10.1371/journal.pone.0041361
Jones PA, Issa J-PJ, Baylin S. Targeting the cancer epigenome for therapy. Nat Rev Genet 2016;17:630-641. https://doi.org/10.1038/nrg.2016.93